PKM2 in carcinogenesis and oncotherapy
Metrics: PDF 1205 views | HTML 1843 views | ?
Xia He1,*, Suya Du2,*, Tiantian Lei2,*, Xiang Li2,*, Yilong Liu3, Hailian Wang4, Rongsheng Tong1 and Yi Wang1
1Department of Pharmacy, Sichuan Academy of Medical Science & Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, China
2School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610054, China
3Department of Pharmacy, The People’s Hospital of Leshan, Leshan, Sichuan 614000, China
4Institute of Organ Transplantation, Sichuan Academy of Medical Science & Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, China
*These authors have contributed equally to this work
Yi Wang, email: firstname.lastname@example.org
Rongsheng Tong, email: email@example.com
Keywords: PKM2; Warburg effect; aerobic glycolysis; carcinogenesis; oncotherapy
Received: August 16, 2017 Accepted: October 28, 2017 Published: November 20, 2017
Tumor cell metabolism is characterized by abundant glucose consumption and aerobic glycolysis. And pyruvate kinase M2 (PKM2) plays a decisive role in glycolysis, significantly contributing to the Warburg effect, tumor growth, angiogenesis, cell division, metastasis and apoptosis. To date, researchers have unraveled the potential of pyruvate kinase M2 as an antitumor target, which suggests a new orientation for oncotherapy. Herein, we focus on the role of pyruvate kinase M2 in tumor cell development and its function as a potential new therapeutic target for tumor treatment. Besides, research actuality on pyruvate kinase M2-dependent glycometabolism and signaling pathway in tumors is also summarized, providing valuable suggestions for further study in this field.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.